|
|
 |
|
Viewing report
|
|
|
|
U.S. Hyaluronic Acid-Based Biomaterials Markets
Frost & Sullivan, March 2002
Growing Health Needs of Elderly Spur Demand for New Biomaterial Therapies
As the number of elderly people in the United States increases, demand for biomaterials used in the treatment of osteoarthritis, cataracts, and facial wrinkling will rise significantly. For those applications, physicians will steadily turn to products based on hyaluronic acid (HA), a natural substance that gives structure to tissue, lubricates movable parts, and absorbs shock in joints. Because the introduction of HA stimulates cells to produce new, healthy HA on their own, the materials will quickly become the preferred biomaterial for a variety of applications.
This Frost & Sullivan study analyzes key application markets for HA-based biomaterials, including viscoelastics for cataract surgery, viscosupplementation treatment for osteoarthritis, facial aesthetic implants, and vesicoureteral reflux implants. With its assessment of drivers and restraints and presentation of expert revenue forecasts, this study gives users a comprehensive view of a fast-growing field.
Technological Advantages Over Collagen Increase HA Revenues
Although collagen-based products have been on the market for a long time, HA-based products are expected to displace them in many applications, write the studys authors. For example, treatments using HA-based products tend to last longer, minimizing the number of treatments. Moreover, these products are less likely to cause allergic reactions or pass along certain diseases. Nevertheless, many patients and healthcare providers remain unaware about the advantages of HA products over collagen. To expand the user base for HA products, market participants will have to focus on spreading awareness of their benefits, write the authors. This study, which surveys the competitive landscape and offers strategic recommendations, will help your company create an effective business plan and capitalize on the industrys tremendous potential.
Inadequate Reimbursement Could Slow Revenue Growth
Companies are having trouble getting quick, adequate reimbursement, write the study’s authors. In many instances, doctors will limit their use of HA-based products as a direct result of reimbursement difficulties.
Continuing repayment issues will force participants to dedicate resources to tracking and following up healthcare insurance claims. Some firms have already created departments for this purpose and have seen improvements in speeding the reimbursement process. By identifying potential obstacles, this study will enable you to overcome hurdles and overtake the competition.
Market Participants
Advanced Tissue Sciences
Akorn, Inc.
Alcon Laboratories, Inc.
Allerga
American Home Products
Anika Therapeutics, Inc.
Artes Medical, Inc.
Bausch & Lomb Surgical
Biomatrix
Biomet Orthopedics, Inc.
Bio-Technology General Corp.
Collagenesis, Inc.
Cytosol Ophthalmics, Inc.
DePuy Orthopaedics, Inc.
Fidia S.p.A.
Genzyme Biosurger
INAMED Corp.
Johnson & Johnson
Novartis
Obagi Medical Products, Inc.
OrthoLogic Corp.
Pharmacia & Upjohn
Priority Healthcare Corp.
Q-Med Scandinavia, Inc.
Q-Med, Inc.
Sanofi-Synthelabo Inc.
Smith & Nephew Inc./Orthopaedic Division
Staar Surgical Co.
Wyeth
Zimmer
Customers who bought this item also bought
Collagen and HA-Based Biomaterials - Global Strategic Business Report
U.S. Markets for Biomaterial Applications of Hyaluronic Acid (HA)
Collagen and HA-based Biomaterials - Global Trends
The 2009-2014 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in Asia
The 2009-2014 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in Europe
The 2009-2014 World Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials
The 2009-2014 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in Oceana
The 2009-2014 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in India
The 2009-2014 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in Japan
The 2009-2014 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in Africa & the Middle East
The 2009-2014 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in Latin America
The 2009-2014 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in North America & the Caribbean
|
|
|
|
